-
Mashup Score: 0The Cancer News Daily - 1 year(s) ago
The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and... - 1 year(s) ago
iFrame is not supported! Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How can Anti-CD38 help patients with Relapsed/Refractory Multiple Myeloma (RRMM)? This study that we pres…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 A video update on the retrospective EHR-S study is available! Discover the patient outcomes by Joshua Richter, MD @JoshuaRichterMD @TischCancer @IcahnMountSinai @MountSinaiNYC #ASH2022 #MultipleMyeloma #MMSM Read and Share the Article Here: https://t.co/Nl2OJdiQV4 https://t.co/WhCeX9EKDK
-
-
Mashup Score: 0
Keeping Pace with Rapid Advancements in Multiple Myeloma Care.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join Ajai Chari, MD and other #hematology experts in San Francisco for live updates and data from the ASH Annual Meeting! Sign up now and tune in at 6 PM PT: https://t.co/y2t9c10WSF #gotoPER #ASH2022 https://t.co/0eSEXQpiEE
-
-
Mashup Score: 0The Cancer News Daily - 1 year(s) ago
The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD
Source: paper.liCategories: Latest Headlines, Oncologists2Tweet-
The latest The Cancer News Daily! https://t.co/ODUTT09CY2 Thanks to @TheCancerLetter @FightCRC @oncologytube #ash2022 #multiplemyeloma
-
-
Mashup Score: 0
Keeping Pace with Rapid Advancements in Multiple Myeloma Care.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
If you’re a busy clinician wanting to stay informed on emerging trends on multiple myeloma, join us in San Franciso for our live panel discussion! Register now to learn more: https://t.co/fo4zaFGPBf #gotoPER #ASH2022 #hematology https://t.co/UPnUh9Qs01
-
-
Mashup Score: 0HOME - Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes - 1 year(s) ago
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Don’t miss our highlights from #ASH2022 on equalizing inequities in multiple myeloma featuring Sikander Ailawadhi MD; Craig Cole MD; & Anita D'Souza MD! Register now for free access: https://t.co/D50gz7iqZm #gotoPER #ASH2022 #hematology https://t.co/8O0DxoLLK8
-
-
Mashup Score: 0
Keeping Pace with Rapid Advancements in Multiple Myeloma Care.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join our ASH Rapid Highlights series in San Francisco! Get access to noteworthy data presented at the ASH Annual Meeting. Learn more here: https://t.co/5PuOtqYiS2 #gotoPER #ASH2022 #hematology https://t.co/1cmVdSR7RY
-
-
Mashup Score: 0
The PIM1 kinase inhibitor TP-3654 was well tolerated and showcased preliminary signs of activity, including spleen volume reduction, symptom improvement, and broad cytokine reduction, in patients with myelofibrosis who were previously treated with or were ineligible for a JAK inhibitor.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
TP-3654 Showcases Early Signs of Tolerability, Clinical Activity in Myelofibrosis @FirasElChaer @uvahealthnews #mpnsm #ASH2022 https://t.co/AfpMppytKx
-
-
Mashup Score: 0HOME - Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes - 1 year(s) ago
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Review data on how the biology of multiple myeloma varies across patients from different racial and ethnic backgrounds. Register now to learn more: https://t.co/KnV1WUmAs0 #gotoPER #ASH2022 #hematology https://t.co/K4q0nyKy9N
-
-
Mashup Score: 2Samhouri Discusses Practice Changing Data in the DLBCL Space - 1 year(s) ago
In an interview with Targeted Oncology, Yazan Samhouri, MD, discussed new agents, clinical trials, and developments creating change in diffuse large B-cell lymphoma, as well as the key takeaways from ASH 2022.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In an interview with Targeted Oncology, @yazansamhouri MD, discussed new agents, clinical trials, and developments creating change in diffuse large B-cell lymphoma, as well as the key takeaways from #ASH2022. #DLBCL #lymsm | @AHNtoday https://t.co/i3Rz2LOFb2 https://t.co/HiM94raZmh
-
The latest The Cancer News Daily! https://t.co/bbVWu8ziSV Thanks to @MDAndersonNews @StJude @oncologytube #ash2022 #multiplemyeloma